Belite Bio (NASDAQ:BLTE) and Tyra Biosciences (NASDAQ:TYRA) Critical Comparison

Belite Bio (NASDAQ:BLTE) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Belite Bio and Tyra Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1	1	6	0	2.63
Tyra Biosciences	1	1	11	1	2.86

Belite Bio presently has a consensus target price of $203.00, suggesting a potential upside of 46.93%. Tyra Biosciences has a consensus target price of $46.00, suggesting a potential upside of 70.43%. Given Tyra Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Tyra Biosciences is more favorable than Belite Bio.

Profitability

This table compares Belite Bio and Tyra Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Tyra Biosciences	N/A	-42.66%	-39.79%

Earnings and Valuation

This table compares Belite Bio and Tyra Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61 million	($2.53)	-54.61
Tyra Biosciences	N/A	N/A	-$119.95 million	($2.18)	-12.38

Belite Bio is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Belite Bio has a beta of -1.24, meaning that its share price is 224% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.

Summary

Tyra Biosciences beats Belite Bio on 8 of the 12 factors compared between the two stocks.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

About Tyra Biosciences

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.